To print: Select File and then Print from your browser's menu

Title: Landmark Trials Demonstrate Benefits of Remicade (Infliximab) in Patients With Ulcerative Colitis

"Landmark Trials Demonstrate Benefits of Remicade (Infliximab) in Patients With Ulcerative Colitis"

Long-Term Phase 3 Data Show Treatment with Remicade Achieves Clinical Response, Steroid-Free Remission, and Mucosal Healing Through 1 Year HORSHAM, PA, and KENILWORTH, NJ -- December 8, 2005 -- Landmark studies published today in The New England Journal of Medicine demonstrate the benefits of treatment with Remicade(R) (infliximab) in patients with ulcerative colitis (UC). At week 8, in both the 54-week ACT 1 trial and the 30-week ACT 2 trial, statistically significant differences in the proportion of patients in clinical response, clinical remission, and with mucosal healing were shown in UC patients treated with Remicade versus those receiving placebo. In particular, approximately two-thirds of UC patients treated with Remicade achieved the primary endpoint of clinical response, defined as improvement in signs and symptoms. Moreover, more than half had mucosal healing and more than one-third were in clinical remission. Furthermore, in both ACT 1 and ACT 2, nearly one-quarter of Remicade patients receiving corticosteroids at baseline were in remission and steroid-free by week 30. In both ACT 1 and ACT 2, a significantly greater proportion of patients treated with Remicade compared with placebo achieved clinical response, clinical remission, and mucosal healing from week 8 through the end of each trial (week 54 in ACT 1 and week 30 in ACT 2). A major advance in the treatment of UC, Remicade is the first and only biologic indicated in the United States for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately-to-severely active UC who have had an inadequate response to conventional therapy. This approval was based on the 30-week data from both trials. "These long term results highlight the benefits of Remicade for the treatment of UC," said William J. Sandborn, MD, professor of medicine, Mayo Clinic College of Medicine, head of the Inflammatory Bowel Disease (IBD) Interest Group, director of the IBD Clinical Research Unit at Mayo Medical Center, and lead study investigator. "These data demonstrate that many patients treated with Remicade experienced not only a reduction in symptoms but had remission of their colitis and mucosal healing, findings that support a new therapeutic approach and standard of care for physicians and their UC patients." UC is a chronic disease affecting more than 1.2 million people in the U.S. and Europe for whom there is no medical cure. Currently, there are no other biologic therapies approved to treat moderate to severe UC. Characterized by inflammation and ulceration of the inner lining of the colon, UC symptoms can often include weight loss, severe -- sometimes uncontrollable -- bloody diarrhea, fatigue, and frequent abdominal pain. Alternative treatments are limited and, if conventional treatments do not control the progression of the disease, many patients may have to face surgical removal of the colon. "Achieving and maintaining improvements over time are challenging goals in the treatment of ulcerative colitis, particularly in patients that do not respond to conventional medications such as steroids," said Paul Rutgeerts, MD, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium, and lead investigator of the ACT 1 study. "Remicade has, for several years, demonstrated efficacy in the treatment of Crohn's disease, and now has proven its ability to be an effective therapy for patients with ulcerative colitis, for which there are limited treatment options." The efficacy of Remicade in the treatment of inflammatory bowel disease is well established in adults. First approved in 1998 for Crohn's disease (CD), Remicade remains the only anti-tumor necrosis factor (TNF-alpha) therapy indicated for the treatment of moderately to severely active CD in patients who have had an inadequate response to conventional therapy. Recently, Remicade also became the only biologic approved by the US Food and Drug Administration (FDA) for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately-to-severely active UC who have had an inadequate response to conventional therapy. About ACT 1 and ACT 2 ACT 1 and ACT 2 were multicenter, Phase 3, randomized, double-blind, placebo-controlled, clinical trials conducted to evaluate the safety and efficacy of Remicade for the treatment of patients with moderately-to-severely active UC who experienced an inadequate response to conventional therapy. A total of 728 patients with active UC who were unresponsive to at least one standard therapy, including corticosteroids, other immunosuppressants, or 5-ASAs, were enrolled in ACT 1 (n=364) and ACT 2 (n=364). Patients in ACT 1 and ACT 2 had endoscopic evidence of moderate or severe UC (total Mayo score of 6 to 12) and an endoscopy score >/=2. ACT 1 patients received treatment with placebo or Remicade 5 mg/kg or Remicade 10 mg/kg at weeks 0, 2, and 6 and then every eight weeks through week 46 and had their last evaluation at week 54. ACT 2 patients received treatment with placebo or Remicade 5 mg/kg or Remicade 10 mg/kg at weeks 0, 2, and 6 and then every 8 weeks through week 22 and had their last evaluation at week 30. In ACT 1, at week 8, 69% of patients in the Remicade 5 mg/kg group and 62% of patients in the Remicade 10 mg/kg group were in clinical response, compared with 37% of patients in the placebo group (P less than 0.001 for both comparisons). In ACT 2, at week 8, 65% of patients in the Remicade 5 mg/kg group and 69% of patients in the Remicade 10 mg/kg group were in clinical response compared with 29% of patients in the placebo group (P <.001 for both comparisons). In both studies, the proportions of patients who achieved clinical response or clinical remission at weeks eight and 30 in ACT 1 and ACT 2 and week 54 in ACT 1 were significantly greater among patients treated with Remicade 5 mg/kg and 10 mg/kg than placebo-treated patients (P less than or equal to 0.003 for all comparisons with placebo). The rates of clinical response were similar between the corticosteroid-refractory and corticosteroid-responsive subgroups. The proportions of patients with sustained clinical response or sustained clinical remission were significantly higher in each Remicade group than in the placebo group (P less than or equal to 0.002 for all comparisons with placebo). Additionally, the proportion of patients treated with Remicade 5 mg/kg and 10 mg/kg who achieved mucosal healing at weeks 8 and 30 (in ACT 1 and ACT 2) and at week 54 (in ACT 1) was significantly greater than that for the placebo-treated patients (P less than or equal to 0.009 for all comparisons with placebo). Furthermore, 61% of the patients in ACT 1 and 51% of the patients in ACT 2 were receiving corticosteroids at baseline. The baseline median daily corticosteroid dose was 20 mg/day in both studies. Of the patients who were receiving corticosteroids at baseline, the proportion of patients who were in clinical remission and had discontinued corticosteroids was significantly greater in the 5 mg/kg Remicade group versus the placebo group at week 30 (P = 0.030 for ACT 1 and P = 0.010 for ACT 2); and at week 54 (P = 0.006 for ACT 1), an important factor for patients with UC who may experience considerable morbidity as a result of corticosteroids. The serious adverse events reported in these trials were similar to those reported in previous Remicade clinical trials. See Important Safety Information below. About Remicade Remicade is a monoclonal antibody that specifically targets TNF-alpha, which has been shown to play a role in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Remicade is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and the only agent approved for the treatment of both RA and CD in North America, the EU and Japan. The safety and efficacy of Remicade have been well established in clinical trials over the past 12 years and through commercial experience with over 600,000 patients treated worldwide. In the U.S., Remicade, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active RA. Remicade is the only biologic indicated for the treatment of patients with moderately-to-severely active CD who have had an inadequate response to conventional therapy. Remicade is also indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing CD. In December 2004, Remicade was approved for reducing signs and symptoms in patients with active AS. On May 13, 2005, Remicade was approved for reducing signs and symptoms of active arthritis in patients with PsA. Additionally, on September 15, 2005, Remicade was approved for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy. This approval makes Remicade the first and only biologic approved for the treatment of moderate to severe UC. In the EU, Remicade is indicated for the treatment of severe, active CD in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. Remicade also is indicated for the treatment of fistulizing, active CD in patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy). For RA patients in the EU, Remicade, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in patients with active disease when the response to disease-modifying drugs, including methotrexate, has been inadequate, and in patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs. In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated. In the EU, Remicade is also indicated for the treatment of AS in patients who have severe axial symptoms, elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. Remicade, in combination with methotrexate, is also approved for the treatment of active and progressive PsA in patients who have responded inadequately to disease modifying anti-rheumatic drugs. Additionally, in September 2005, Remicade was approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or have a contraindication to, or are intolerant of other systemic therapy including cyclosporine, methotrexate or psoralen plus ultraviolet A light (PUVA). Remicade is unique among available anti-TNF biologic therapies. Unlike self-administered therapies that require patients to inject themselves frequently, Remicade is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. In RA (3 mg/kg), CD (5 mg/kg), PsA (5 mg/kg), and UC (5 mg/kg), Remicade is a two-hour infusion administered every 8 weeks, following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, Remicade patients may require as few as six treatments each year. In AS (5 mg/kg), Remicade is a two-hour infusion administered every 6 to 8 weeks, following a standard induction regimen that requires treatment at weeks 0, 2 and 6. Centocor discovered Remicade and has exclusive marketing rights to the product in the United States. Schering-Plough markets Remicade in all countries outside of the United States, except in Japan and parts of the Far East where Tanabe Seiyaku, Ltd. markets the product and in China where Xian- Janssen markets Remicade. SOURCE: Centocor, Inc.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.